Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

A paradoxical severe decrease in serum HDL-cholesterol after treatment with a fibrate.

M A Crook1, J Lynas, R Wray

  • 1Department of Chemical Pathology, Guy's, St Thomas's, and University Lewisham Hospital, London, UK. martin.crook@gstt.sthames.nhs.uk

Journal of Clinical Pathology
|November 7, 2000
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Urolithiasis: Don't forget the rarities.

Annals of clinical biochemistry·2021
Same author

Analbuminaemia: clinical features and associated hypercholesterolaemia.

Annals of clinical biochemistry·2016
Same author

Low serum creatine kinase activity in hospital patients.

British journal of biomedical science·2016
Same author

The lipaemic index: clinical observations.

British journal of biomedical science·2015
Same author

Pro-protein convertase subtilisin/kexin 9 concentrations correlate with coronary artery disease atheroma burden in a Pakistani cohort with chronic chest pain.

International journal of clinical practice·2015
Same author

Angiographic coronary artery disease and high-sensitivity troponin-T in a native Pakistani cohort presenting with chronic chest pain.

International journal of clinical practice·2014
Same journal

Defining biochemical, pathological and molecular factors prognostic in terms of disease control and survival in high-grade extremity soft tissue sarcoma: a scoping review.

Journal of clinical pathology·2026
Same journal

MILGDF: a multi-task, instance-level supervised model for oral squamous cell carcinoma integrating local-global attention and dynamic decision fusion.

Journal of clinical pathology·2026
Same journal

Paediatric B-lymphoblastic leukaemia with low peripheral blasts: a potential diagnostic pitfall.

Journal of clinical pathology·2026
Same journal

MRI-targeted versus systematic needle core biopsies in prostate cancer: a patient-based analysis of potential diagnostic and biologic underestimation.

Journal of clinical pathology·2026
Same journal

Basal plasmacytosis and eosinophilia for distinguishing inflammatory bowel disease from gastrointestinal tuberculosis on mucosal biopsy.

Journal of clinical pathology·2026
Same journal

Assay-dependent variability in free thyroxine (FT4): differential interference related to immunoassay design in a patient with subclinical hypothyroidism.

Journal of clinical pathology·2026
See all related articles

Fibrate drugs, like bezafibrate, can paradoxically lower cardioprotective high-density lipoprotein (HDL) cholesterol. This case report details such a decline and discusses potential mechanisms and implications.

Area of Science:

  • Pharmacology
  • Cardiology
  • Nephrology

Background:

  • Fibrate medications are commonly prescribed to manage dyslipidemia.
  • A paradoxical decrease in high-density lipoprotein (HDL)-cholesterol has been anecdotally reported with fibrate use.
  • The clinical significance and underlying mechanisms of this HDL decline remain unclear.

Observation:

  • This report details a patient experiencing a significant decrease in serum HDL-cholesterol while on combined therapy with simvastatin and bezafibrate.
  • The patient also presented with impaired renal function, suspected to be interstitial nephritis.

Findings:

  • The combined use of simvastatin and bezafibrate was associated with a notable reduction in HDL-cholesterol levels.
  • The observed decline in HDL-cholesterol in this patient aligns with previous limited reports on fibrate-induced HDL reduction.

Related Experiment Videos

Implications:

  • The paradoxical reduction in HDL-cholesterol may counteract the cardioprotective benefits of fibrates.
  • Further research is warranted to elucidate the mechanisms behind fibrate-induced HDL decline.
  • Clinicians should be vigilant for this adverse effect, especially in patients on combination lipid-lowering therapy.